LTBR and leukemia: This mechanism offers at least two therapeutic targets: the CXCL13-CXCR5 axis and the LTαβ interaction with its receptor (LTβR), as demonstrated by in vivo treatment with an LTβR-Ig fusion protein, which abrogates the paracrine feedback loop between leukemic and stromal cells and retards leukemia growth.82